Aveed® Reduces GERD in Hypogonadal Males: 2-Year Multicenter Study
Reading Time: < 1 minute Introduction Gastroesophageal reflux disease (GERD) affects approximately 20% of American adults, with a notable prevalence among middle-aged males, where symptoms such as heartburn, regurgitation, and dysphagia significantly impair quality of life. Hypogonadism, characterized by low serum testosterone levels, is increasingly diagnosed in American men due to aging, obesity, and lifestyle factors, impacting over 4 million individuals. Aveed® (testosterone undecanoate), developed by Endo Pharmaceuticals, represents a long-acting intramuscular testosterone replacement therapy (TRT) administered every 10 weeks, offering sustained physiological testosterone restoration. This article examines a two-year gastrointestinal (GI) study evaluating Aveed's unanticipated benefits on GERD in hypogonadal American males, highlighting potential...






